These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 18619558)

  • 1. Display scaffolds: protein engineering for novel therapeutics.
    Nuttall SD; Walsh RB
    Curr Opin Pharmacol; 2008 Oct; 8(5):609-15. PubMed ID: 18619558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding proteins from alternative scaffolds.
    Nygren PA; Skerra A
    J Immunol Methods; 2004 Jul; 290(1-2):3-28. PubMed ID: 15261569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering novel binding proteins from nonimmunoglobulin domains.
    Binz HK; Amstutz P; Plückthun A
    Nat Biotechnol; 2005 Oct; 23(10):1257-68. PubMed ID: 16211069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Advances in the Scaffold Engineering of Protein Binders.
    Ahmadi MKB; Mohammadi SA; Makvandi M; Mamouei M; Rahmati M; Dehghani H; Wood DW
    Curr Pharm Biotechnol; 2021; 22(7):878-891. PubMed ID: 32838715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineered protein scaffolds for molecular recognition.
    Skerra A
    J Mol Recognit; 2000; 13(4):167-87. PubMed ID: 10931555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DARPins and other repeat protein scaffolds: advances in engineering and applications.
    Boersma YL; Plückthun A
    Curr Opin Biotechnol; 2011 Dec; 22(6):849-57. PubMed ID: 21715155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of novel protein scaffolds as alternatives to whole antibodies for imaging and therapy: status on discovery research and clinical validation.
    Wurch T; Lowe P; Caussanel V; Bes C; Beck A; Corvaia N
    Curr Pharm Biotechnol; 2008 Dec; 9(6):502-9. PubMed ID: 19075688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineered antibodies take center stage.
    Huston JS; George AJ
    Hum Antibodies; 2001; 10(3-4):127-42. PubMed ID: 11847424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineering reprogrammable RNA-binding proteins for study and manipulation of the transcriptome.
    Abil Z; Zhao H
    Mol Biosyst; 2015 Oct; 11(10):2658-65. PubMed ID: 26166256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the development of novel protein scaffolds based therapeutics.
    Azhar A; Ahmad E; Zia Q; Rauf MA; Owais M; Ashraf GM
    Int J Biol Macromol; 2017 Sep; 102():630-641. PubMed ID: 28412342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific applications of non-immunoglobulin scaffold binders.
    Hober S; Lindbo S; Nilvebrant J
    Methods; 2019 Feb; 154():143-152. PubMed ID: 30287281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineered protein scaffolds as next-generation antibody therapeutics.
    Gebauer M; Skerra A
    Curr Opin Chem Biol; 2009 Jun; 13(3):245-55. PubMed ID: 19501012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stability engineering of the human antibody repertoire.
    Rouet R; Lowe D; Christ D
    FEBS Lett; 2014 Jan; 588(2):269-77. PubMed ID: 24291820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Domain antibodies: proteins for therapy.
    Holt LJ; Herring C; Jespers LS; Woolven BP; Tomlinson IM
    Trends Biotechnol; 2003 Nov; 21(11):484-90. PubMed ID: 14573361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monobodies: antibody mimics based on the scaffold of the fibronectin type III domain.
    Koide A; Koide S
    Methods Mol Biol; 2007; 352():95-109. PubMed ID: 17041261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The nature of an ideal therapeutic human antibody.
    Glassy MC; Koda K
    Expert Opin Biol Ther; 2002 Jan; 2(1):1-2. PubMed ID: 11772335
    [No Abstract]   [Full Text] [Related]  

  • 17. Engineered proteins as specific binding reagents.
    Binz HK; Plückthun A
    Curr Opin Biotechnol; 2005 Aug; 16(4):459-69. PubMed ID: 16005204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phage display for engineering and analyzing protein interaction interfaces.
    Sidhu SS; Koide S
    Curr Opin Struct Biol; 2007 Aug; 17(4):481-7. PubMed ID: 17870470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing therapeutic antibody function: progress with Fc domain engineering.
    Kaneko E; Niwa R
    BioDrugs; 2011 Feb; 25(1):1-11. PubMed ID: 21033767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative non-antibody scaffolds for molecular recognition.
    Skerra A
    Curr Opin Biotechnol; 2007 Aug; 18(4):295-304. PubMed ID: 17643280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.